Drugs / Isophane insulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07532577 | Apr → Jul 2026 overdue | delirium | Radboud University Medical Center | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isophane insulin | “Intranasal isophane insulin administered twice daily. Each administration consists of two sprays of 10 IU (0.1 ml) in alternating nostrils, totalling to 40 IU per day.” NCT07532577 ↗1“Isophane insulin” NCT05565976 ↗ |
| Route | Intranasal | “Intranasal isophane insulin administered twice daily.” NCT07532577 ↗ |